TNP-2092

DB16312InvestigationalSmall molecule

TNP-2092 is under investigation in clinical trial NCT03964493 (TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection).

Chemical structure of TNP-2092
Formula / weight
C65H81FN6O15 · 1205.388 g/mol (avg)
Code names
CBR-2092 · TNP-2092

Resolves to

Compound
UNIIW2P7EF7O6OCAS922717-97-3
Structure
InChIKeyOPZFMLLAJBIKAN-JNEXSVMGSA-NSMILESCO[C@H]1C=CO[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=C\C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@H](C)[C@H](OC(C)=O)[C@H]1C)C(\C=N\N1CCC(CC1)N(C)C1(CC1)[C@@H]1CCN(C1)C1=C(C)C3=C(C=C(C(O)=O)C(=O)N3C=C1F)C1CC1)=C2O
Targets
P0AFI2parCP0A0K8gyrBP20831gyrA

What you can answer from here — as of April 23, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with TNP-2092, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In